Article Text

Download PDFPDF
Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma
  1. Alexander Lin1,
  2. Sirui Ma1,
  3. Farrokh Dehdashti2,
  4. Stephanie Markovina1,
  5. Julie Schwarz1,
  6. Barry Siegel2,
  7. Matthew Powell3 and
  8. Perry Grigsby1
  1. 1 Department of Radiation Oncology, Washington University in Saint Louis, St Louis, Missouri, USA
  2. 2 Department of Radiology, Washington University in Saint Louis, St Louis, Missouri, USA
  3. 3 Division of Gynecology Oncology, Washington University in Saint Louis, St Louis, Missouri, USA
  1. Correspondence to Dr Perry Grigsby; pgrigsby{at}wustl.edu

Abstract

Objective The detection of distant metastatic disease in cervical cancer patients at diagnosis is critical in accurate prognostication and directing treatment strategies. This study describes the frequency and sites of distant metastatic disease at diagnosis in patients with cervical cancer as detected by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET).

Methods Patients with newly diagnosed cervical cancer underwent pre-treatment whole-body FDG-PET starting in 1997 at an academic institution. Patients with evidence of distant FDG-avid disease, defined as disease outside of typical sites of lymphatic spread, were included for analyses. Patients were not surgically staged, but biopsy to confirm metastatic disease was attempted at the discretion of the treating physicians. Overall survival was calculated using Kaplan-Meier analysis.

Results From 1997 to 2017, 72 (6.2%) of 1158 consecutively evaluated cervical cancer patients exhibited FDG-avid distant disease at diagnosis; 27 (38%) of these had biopsy confirmation of distant disease. Only 35 (49%) of FDG-detected metastases were clinically apparent. The sites of distant disease were lung (35%), multiple sites (25%), omentum (16.5%), bone (16.5%), and liver (7%). There were 12 (17%) patients with distant disease who did not display FDG-avid lymph nodes. Median overall survival among patients with distant FDG-avid disease was 7.0 months (95% CI 4.3 to 9.7). Patients with multiple sites of distant disease demonstrated the worst overall survival.

Conclusions Distant metastatic disease detected by FDG-PET is found in 6.2% of patients with cervical cancer at the time of initial diagnosis and the most common site of disease is the lung. Further prospective investigation is warranted to delineate best treatment practices for cervical cancer patients presenting with distant metastases.

  • cervical cancer
  • FDG-PET
  • distant metastasis
  • omental
  • peritoneal
View Full Text

Statistics from Altmetric.com

Footnotes

  • AL and SM are joint first authors.

  • Contributors SM: data curation, methodology, writing-original draft. AL: data curation, methodology, formal analysis, writing-original draft. FD: review and editing. SM: review and editing. JS: review and editing. BS: review and editing. MP: review and editing. PG: conceptualization, review and editing.

  • Funding PG is supported by NIH R21 CA223799-01. JS is supported by NIH R01 CA181745-01. SM is supported by NIH K12 CA167540. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.